Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF levels of Aβ and phosphorylated tau, as assessed by immunoassays, correlate with AD disease state and neurodegenerative pathology, but more disease specific information can be gleaned from assessment of the specific post-translational modifications of tau [37,59].”
From Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease (2025) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationRevisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 4×
“…biomarker compared with its measurement in CSF. Blood plasma amyloid-β (Aβ) 42/40 ratio recapitulates with accuracy change on Aβ42/40 ratio detected in CSF and associates with measures of brain amyloid plaques by amyloid PET scans (Ovod et al., 2017; Nakamura et al., 2018; Schindler et al., 2019).”
BackgroundMethodInfluentialSelf-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Cited by
Items 201–300 of 476
Ashford, M. T., Veitch, D. P., Neuhaus, J. M., Nosheny, R. L., Tosun, D., & Weiner, M. W. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12253 · Cited by 23
Tau kinetics in Alzheimer's disease
Hier, D. B., Azizi, S., Thimgan, M. S., & Wunsch, D. C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1055170 · Cited by 23
“More recent studies show higher values for both CSF and plasma tau (Barthélemy et al., 2020).”
BackgroundPanza, F., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Cirillo, N., Damiani, C., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2233892 · Cited by 22
“namic and therapy mechanism interpretation, and RCT participants’ selection [83].”
BackgroundBlūma, M., Chiotis, K., Bucci, M., Savitcheva, I., Matton, A., Kivipelto, M., Jeromin, A., Santis, G. D., Molfetta, G. D., Ashton, N. J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105504 · Cited by 22
Preanalytical stability of plasma/serum brain‐derived tau
González‐Ortiz, F., Dias, A., Turton, M., Magalhães, R., Kac, P. R., Correia, M. A., Harrison, P., Zetterberg, H., Maia, L. F., Blennow, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13156 · Cited by 22
Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
Rousset, R. Z., Claessen, T., van Harten, A. C., Lemstra, A. W., Pijnenburg, Y. A. L., van der Flier, W. M., den Braber, A., Jeromin, A., Verberk, I. M. W., & Teunissen, C. E. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70003 · Cited by 23
Fu, W., & Ho, P. C. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103058 · Cited by 21
Is blood pTau a reliable indicator of the CSF status? A narrative review
Antonioni, A., Raho, E. M., & Lorenzo, F. D. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07258-x · Cited by 21
“Although most of the included studies evaluate the performance of pTau isoforms by categorising patients from a biomarker point of view, some works show promising results even if patients are categorised from a clinical point of view [e.g. 47, 49, 51].”
Koivumäki, M., Ekblad, L. L., Lantero‐Rodriguez, J., Ashton, N. J., Karikari, T. K., Helin, S., Parkkola, R. K., Lötjönen, J. M. P., Zetterberg, H., Blennow, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01477-w · Cited by 21
(2022) · doi:10.3390/proteomes10030026 · Cited by 20
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 20
“…concentration of tau phosphorylated at position 217 (p-tau217) and the ratio of p-tau217 to non-phosphorylated tau (%p-tau217) have emerged as markers with accuracies similar to that of Food and Drug Administration (FDA)-approved CSF tests for classification of amyloid and tau PET status 34,41–43 .”
Self-citationPassive tau-based immunotherapy for tauopathies
Panza, F., Solfrizzi, V., Daniele, A., & Lozupone, M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98817-9.00029-6 · Cited by 21
Tam, S., Wear, D., Morrone, C. D., & Yu, W. H. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16108 · Cited by 21
Schauer, S. P., Tóth, B. I., Lee, J., Honigberg, L. A., Ramakrishnan, V., Jiang, J. Z., Kollmorgen, G., Bayfield, A., Wild, N., Hoffman, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14346 · Cited by 20
Sadleir, K. R., Gómez, K., Edwards, A. E., Patel, A. J., Ley, M. L., Khatri, A. W., Guo, J., Mahesh, S., Watkins, E. A., Popović, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02888-1 · Cited by 19
“CSF and plasma biomarkers p-tau181 and p-tau231 correlate significantly with Aβ pathology and predict AD onset years in advance [6, 7, 79, 107].”
Wu, F., Li, W., Lu, H., & Li, L. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101003 · Cited by 19
Kjærgaard, D., Nielsen, T. R., Stomrud, E., Palmqvist, S., Bali, D., Dolado, A. O., Janelidze, S., Hansson, O., Waldemar, G., & Simonsen, A. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70315 · Cited by 19
Proteomics Landscape of Alzheimer’s Disease
Jain, A., & Sathe, G. J. (2021) · Proteomes · doi:10.3390/proteomes9010013 · Cited by 19
“measured attomolar concentration of tau isoforms in plasma and reported that p-tau-217 is more accurate than p-tau-181 for detecting abnormal CNS tau metabolism [70].”
Tau: a biomarker of Huntington’s disease
Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19
“Although plasma p-tau181 is a known biomarker of AD [127], p-tau217 is reportedly more accurate [142, 143].”
Considerations for Use of Blood-Based Biomarkers in Epidemiologic Dementia Research
Hayes‐Larson, E., Ackley, S. F., Turney, I. C., Joie, R. L., Mayeda, E. R., Glymour, M. M., & Initiative, A. D. N. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad197 · Cited by 20
Dayarathna, T. K., Roseborough, A. D., Gomes, J., Khazaee, R., Silveira, C. R. A., Borron, K., Yu, S., Coleman, K. K. L., Jesso, S., Finger, E. C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14087 · Cited by 19
Jiang, Y., Zheng, W., Xia, Z., Wong, W. W., Cheng, L. K., Ip, F. C. F., Choi, S. M., Chan, A. L., Lam, C. Y., Ho, K. S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536792123 · Cited by 19
“Nevertheless, pilot studies have indicated that only approximately one - fifth of total tau protein in plasma originates from the brain (14, 37), highlighting the necessity of ultrasensitive detection platforms for accurate measurement of BD - pTau217.”
Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology
Sauvé, F., Gomez-Martínez, R., Mbouamboua, Y., Ternier, G., Nampoothiri, S. S., Dupré, E., Garcia, L., Couralet, M., Dewisme, J., Lebouvier, T., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100003 · Cited by 19
Wakasugi, N., & Hanakawa, T. (2021) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2021.777706 · Cited by 18
Horie, K., Li, Y., Barthélemy, N. R., Gordon, B. A., Hassenstab, J. J., Benzinger, T. L. S., Fagan, A. M., Morris, J. C., Karch, C. M. M., Xiong, C., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26620 · Cited by 18
“These cross-sectional results showed that CSF tau is truncated at multiple sites, and specific MTBR-tau containing the repeat domain 2 (R2) and repeat domain 4 (R4) changed differentially in CSF based on stage of disease progression and were enriched in the insoluble tau deposits of AD brain samples in sporadic AD (sA…”
BackgroundSelf-citationRecent progress of small-molecule-based theranostic agents in Alzheimer's disease
Gao, F., Chen, J., Zhou, Y., Cheng, L., Hu, M., & Wang, X. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00330b · Cited by 18
Liu, X., Jin, Y., Cheng, X., Song, Q., Wang, Y., He, L., & Chen, T. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06530-y · Cited by 18
“…content of p-tau-217 in plasma gradually decreases with AD pathological progress, while the PET signal of total tau in brain gradually increases (Barthélemy et al. 2020; Palmqvist et al. 2020), suggesting that p-tau in blood is a pathological response to AD progression rather than a direct…”
Koike, R., Soeda, Y., Kasai, A., Fujioka, Y., Ishigaki, S., Yamanaka, A., Takaichi, Y., CHAMBERS, J. K., Uchida, K., Watanabe, H., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad359 · Cited by 18
“Detailed statistical analyses are given in Supplemental Tables 1–3. took this test three times, and the average error distance was used as an index of path integration.”
MethodInfluentialComparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
Bali, D., Salvadó, G., Beach, T. G., Serrano, G. E., Atri, A., Reiman, E. M., Jeromin, A., Hansson, O., & Janelidze, S. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02064-2 · Cited by 17
Wu, Y., Wen, Q., Thukral, R., Yang, H., Gill, J., Gao, S., Lane, K. A., Meier, T. B., Riggen, L., Harezlak, J., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207389 · Cited by 17
“Phosphorylated tau might be a better blood biomarker with higher CNS specificity.(40) On the other hand, plasma NfL and GFAP demonstrated significant correlations with their CSF counterparts in TBI(14,39,41) and in Alzheimer disease.”
BackgroundConsensus on rapid screening for prodromal Alzheimer’s disease in China
Huang, L., Li, Q., Lu, Y., Pan, F., Cui, L., Wang, Y., Miao, Y., Chen, T., Li, Y., Wu, J., et al. (2024) · General Psychiatry · doi:10.1136/gpsych-2023-101310 · Cited by 17
“56 64–66 In addition, plasma p-tau181 is tightly associated with the progression of brain tau pathology only in the population with A β +. 67 68 Even in individuals without positive tau-PET, increased levels of plasma p-tau181 and p-tau217 were observed with positive amyloid-PET, 69 70 and p-tau231…”
BackgroundIntracellular tau fragment droplets serve as seeds for tau fibrils
Soeda, Y., Yoshimura, H., Bannai, H., Koike, R., Shiiba, I., & Takashima, A. (2024) · Structure · doi:10.1016/j.str.2024.06.018 · Cited by 17
Long COVID as a Tauopathy: Of “Brain Fog” and “Fusogen Storms”
Sfera, A., Rahman, L., del Campo, C. M. Z.-M., & Kozlakidis, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612648 · Cited by 17
Wang, R., Peng, S., Zhu, J., Xu, Y., Wang, M., Zhang, L., Qiu, Y., Hou, D., Wang, Q., & Liu, R. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1651708 · Cited by 16
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
Rudman, M. D., Ulrich, J. D., & Holtzman, D. M. (2026) · Cell · doi:10.1016/j.cell.2026.06.006 · Cited by 19
Li, L., Che, P., Liu, D., Wang, Y., Li, J., He, D., Liu, T., & Zhang, N. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100092 · Cited by 16
“Unlike p-tau, nonphosphorylated tau is produced in peripheral nerves or tissue [ 34 ], and it is estimated that only approximately 20 % of plasma t-tau comes from the central nervous system [ 35 ].”
Tauopathy after long‐term cervical lymphadenectomy
Wu, C., Yuan, J., Tian, Y., Wang, Y., He, X., Zhao, K., Huang, J., & Jiang, R. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70136 · Cited by 16
“Plasma p-tau217 levels have recently emerged as a new biomarker for supporting the diagnosis of AD, 29,30 with p-tau217 being highly specific for detecting amyloid pathology and potentially rising 20 years before cognitive impairment appears.”
Brain-derived tau for monitoring brain injury in acute ischemic stroke
Vlegels, N., Knuth, N. L., Steiner, K. A., Zhang, L., Vix, A. L., Moumin, D., Mirzen, I., Khalifeh, N., Forster, C., Gesierich, B. G., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adz1280 · Cited by 16
Glaucoma as a Tauopathy—Is It the Missing Piece in the Glaucoma Puzzle?
Passaro, M. L., Matarazzo, F., Abbadessa, G., Pezone, A., Porcellini, A., Tranfa, F., Rinaldi, M., & Costagliola, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216900 · Cited by 16
Kimura, T., Sato, H., Kano, M., Tatsumi, L., & Tomita, T. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13667 · Cited by 15
Kong, S., Wen, X., Wang, Y., Tan, R., Li, H., & Tu, Y. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00568 · Cited by 15
Nashiro, K., Yoo, H. J., Cho, C., Kim, A. J., Nasseri, P., Min, J., Dahl, M. J., Mercer, N., Choupan, J., Choi, P., et al. (2024) · Trials · doi:10.1186/s13063-024-07943-y · Cited by 15
Blum, D., Cailliau, É., Behal, H., Vidal, J., Delaby, C., Buée, L., Allinquant, B., Gabelle, A., Bombois, S., Lehmann, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14169 · Cited by 15
Coulton, J. B., He, Y., Barthélemy, N. R., Jiang, H., Holtzman, D. M., & Bateman, R. J. (2024) · Brain Communications · doi:10.1093/braincomms/fcae247 · Cited by 15
Self-citationDasari, M., Kurian, J. A., Gundraju, S., Raparthi, A., & Medapati, R. V. (2025) · Cureus · doi:10.7759/cureus.79881 · Cited by 15
Overexpression of fibroblast growth factor 13 ameliorates amyloid-β-induced neuronal damage
Zhu, H., Li, R., Xiao, L., Zhang, T., & Ren, D. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.357902 · Cited by 16
“Barthélemy et al. (2020) reported that p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in cerebrospinal fluid.”
BackgroundPost-Translationally Modified Proteoforms as Biomarkers: From Discovery to Clinical Use
Luo, Y. R., Yeung, P. S.-W., Mann, M. W., Zhang, L., Yang, Y. K., & Hoofnagle, A. N. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf094 · Cited by 15
Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer’s Disease
Jung, D. H., Son, G., Kwon, O.-H., Chang, K., & Moon, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081532 · Cited by 14
“CSF Blood AD Pathology Mechanism Core Biomarkers Change Reference Change Reference Aβ42 Reduced [29,46,47] Reduced [48–50] Aβ pathology Aβ42/Aβ40 Reduced [51–53] Reduced [48,50,54] P-tau Increased [55–57] Increased [58–60] Tau pathology T-tau Increased [61–63] Increased [60,64,65]”
BackgroundNeurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen
Andrés‐Benito, P., Vazquez-Costa, J. F., Garzón, N. C. Ñ., Colomina, M. J., Marco, C., González, L., Terrafeta, C., Domínguez, R., Ferrer, I., & Povedano, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073810 · Cited by 13
The interactome of tau phosphorylated at T217 in Alzheimer’s disease human brain tissue
Kavanagh, T., Thierry, M., Balcomb, K., Ponce, J., Kanshin, E., Tapia-Sealey, A., Halliday, G. M., Ueberheide, B. M., Wısnıewskı, T., & Drummond, E. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02881-8 · Cited by 13
“The phosphorylation of specific residues of tau can both act as biomarkers for AD and track progression of the disease [9, 35, 46, 53].”
Genome-wide association study identifies APOE locus influencing plasma p-tau181 levels
Huang, Y., Yang, Y., Wang, H.-F., Shen, X., Tan, L., Yu, J., & Initiative, A. D. N. (2022) · Journal of Human Genetics · doi:10.1038/s10038-022-01026-z · Cited by 13
“The previous studies indicate that plasma tau and CSF tau levels poorly correlate with each other, introducing controversy and casting doubts on the reliability of plasma tau pathology biomarkers [1 – 3].”
Mammalian Models in Alzheimer’s Research: An Update
Sharma, H., Chang, K., Hulme, J., & An, S. S. A. (2023) · Cells · doi:10.3390/cells12202459 · Cited by 13
“Abnormal hyperphosphorylation of tau protein (p-tau) is a key component of NFT, especially the phosphorylation of specific Thr residues (Thr 181, 217, and 231) is a biomarker of AD pathology [71].”
BackgroundOnigbinde, S. B., Solomon, J., Reyes, C. D. G., Daramola, O. E., Fowowe, M., Adeniyi, M., DuBois, K. N., Bakulski, K. M., Kanaan, N. M., Lubman, D. M., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00018 · Cited by 13
Chong, J. R., Hilal, S., Venketasubramanian, N., Schöll, M., Ashton, N. J., Zetterberg, H., Chen, C. P., & Lai, M. K. P. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100615 · Cited by 12
Biomarkers and Risk Assessment of Alzheimer’s Disease in Low- and Middle-Income Countries
Adewale, B. A., Coker, M. M., Ogunniyi, A. O., Kalaria, R. N., & Akinyemi, R. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221030 · Cited by 12
Blood-based biomarkers of Alzheimer’s disease—A guideline for clinical use
Shi, J., Ou, Q., & Chen, X. (2024) · Medicine Plus · doi:10.1016/j.medp.2024.100057 · Cited by 11
Tau biomarkers for neurodegenerative diseases: Current state and perspectives
Vacchi, E., Ruíz‐Barrio, I., & Melli, G. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107772 · Cited by 12
Hayes, C. A., Najmi, Z., Contreras, J. A., Dharmapuri, A., Winston, C. N., & *The Health and Aging Brain Study (HABS‐HD) Study Team (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70269 · Cited by 11
“8–12”
Xin, J., Huang, X., Sun, Y. H., Jiang, H.-S., Jin, F., Yu, N., Guo, F., Ye, F., Xiao, J., Le, W., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.838223 · Cited by 12
“Considering the consistency of CSF and plasma p-tau (Barthélemy et al., 2020; Palmqvist et al., 2020; Janelidze et al., 2021a), it is speculated that the plasma p-tau217 may have a similar trajectory to CSF p-tau217.”
BackgroundWan, K., Yin, W., Tang, Y., Zhu, W., Wang, Z., Zhou, X., Zhang, W., Zhang, C., Yu, X., Zhao, W., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221100 · Cited by 11
Phosphorylated tau in Alzheimer’s disease
Telser, J., Grossmann, K., Wohlwend, N., Risch, L., Saely, C. H., & Werner, P. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.05.001 · Cited by 12
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 11
“Given that only one-fifth of plasma t-tau originates from the CNS [110], assays that specifically measure brain-derived tau levels are needed.”
BackgroundInfluentialBiofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 11
Hällqvist, J., Pinto, R. C., Heywood, W., Cordey, J. G., Foulkes, A., Slattery, C. F., Leckey, C. A., Murphy, E. C., Zetterberg, H., Schott, J. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813758 · Cited by 12
Chen, C. D., Ponisio, M. R., Lang, J. A., Flores, S., Schindler, S. E., Fagan, A. M., Morris, J. C., & Benzinger, T. L. S. (2023) · Journal of Alzheimer’s Disease · doi:10.3233/jad-230032 · Cited by 10
Brain and plasmatic CLUSTERIN are translational markers of Alzheimer's disease
Tournier, B. B., Ceyzériat, K., Marteyn, A., Amossé, Q., Badina, A. M., Tsartsalis, S., Herrmann, F. R., Zekry, D., & Millet, P. (2024) · Brain Pathology · doi:10.1111/bpa.13281 · Cited by 10
Ruling in, ruling out: the clinical utility of plasma biomarkers in diagnosis of Alzheimer’s disease
Wisch, J. K., & Ances, B. M. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198725 · Cited by 10
“As amyloid accumulates, it triggers downstream processes, including the hyperphosphorylation of tau proteins at more than 40 known amino acid sites (8) — events that have been quantified in both CSF (9, 10) and, more recently, in plasma (11).”
Biel, D., Steward, A., Dewenter, A., Dehsarvi, A., Zhu, Z., Roemer, S. N., Frontzkowski, L. K., Hirsch, F., Palleis, C., Höglinger, G. U., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70783 · Cited by 11
Mao, X., Wang, Y., Luan, Y., Wang, Y., Wang, J., Dai, W., Guan, Y., Huang, Q., Gunn, R. N., Ossenkoppele, R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00906-0 · Cited by 10
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
Trautwig, A. N., Shantaraman, A., Chung, M., Dammer, E. B., Ping, L., Duong, D. M., Watson, C. M., Petrucelli, L., Ward, M. E., Glass, J. D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117142 · Cited by 10
Ni, W., Jagust, W. J., & Wang, D. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00424 · Cited by 10
P-tau217 as a Biomarker in Alzheimer’s Disease: Applications in Latin American Populations
Varela-Vidales, C. A., Martínez-Hernández, A., Hernández-Castellanos, E., & Delgado-Lara, D. L. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146633 · Cited by 10
Haq, M. Z. U., Zhao, X., Apori, S. O., Singh, B., & Tian, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199282 · Cited by 9
“…biomarkers testing is less invasive, more accessible, and cost-effective than PET imaging or lumbar puncture [134], its clinical application is hindered by the ultra-low concentrations of biomarkers, and the difficulty is differentiating pathological signals from normal physiological levels [135].”
Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System
Koppisetti, R. K., Barthélemy, N. R., Horie, K., Ly, C. V., Roberts, K. F., Koutarapu, S., Perrin, R. J., Franklin, E. E., Pedicone, C., Orrick, J., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78300 · Cited by 11
“14,17,71 In contrast, we found CSF big tau exon 4a-L increased with age but no signi fi cant changes of the CSF big tau exon 4a-L peptides in either preclinical AD or in individuals with mild cognitive impairment due to AD.”
Self-citationProtein Biomarkers for the Diagnosis of Alzheimer’s Disease at Different Stages of Neurodegeneration
Pérez, M., Hernández, F., & Ávila, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186749 · Cited by 9
“At the very early stage, phosphotau 181 and 217 could be found in CSF [47].”
BackgroundFader, K. A., Zhang, J., Menetski, J. P., Thadhani, R., Antman, E. M., Friedman, G. S., Ramaiah, S. K., & Vaidya, V. S. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000204 · Cited by 9
Tanycytes are degraded in Alzheimer’s Disease, disrupting the brain-to-blood efflux of TauPreprint
Sauvé, F., Ternier, G., Dewisme, J., Lebouvier, T., Dupré, E., Danis, C., Rasika, S., Kim, Y., Ciofi, P., Giacobini, P., et al. (2022) · medRxiv · doi:10.1101/2022.05.04.22274181 · Cited by 9
“concentrations have been previously compared and found to be higher in the CSF and plasma of AD patients compared to normal subjects (40, 41), the importance of the plasma-”
ResultOrr, M. E., Garbarino, V. R., Palavicini, J., Melendez, J., Barthélemy, N. R., He, Y., Kautz, T. F., Lopez‐Cruzan, M., Mathews, J. J., Xu, P., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3994894/v1 · Cited by 10
Self-citationMukherjee, S., Coyle, R. A., Dubois, C., Perez, K. A., McLean, C., Masters, C. L., & Roberts, B. R. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02914-2 · Cited by 9
Singh, R., Mishra, A., Kumar, V., Gupta, A., Zehra, S., Rani, N., Dhingra, R., Modi, G. P., Inampudi, K. K., Nikolajeff, F. K., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120761 · Cited by 8
Das, S., Awasthi, A., Rawal, R. K., & Bhatia, R. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-025-05549-x · Cited by 8
Proteomic Markers and Early Prediction of Alzheimer’s Disease
Zakharova, N. V., Bugrova, A. E., Indeykina, M. I., Fedorova, Y. B., Колыхалов, И. В., Si, G., Николаев, Е. Н., & Kononikhin, A. S. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922080089 · Cited by 8
“The levels of the core AD biomarkers in blood plasma are significantly lower than in CSF; however, they have also been used to confirm the diagnosis of AD [19, 31-35].”
BackgroundMethodResultInfluentialPlasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET
Cogswell, P. M., Wiste, H. J., Weigand, S. D., Therneau, T. M., Griswold, M. E., Braunstein, J. B., West, T., Verghese, P. B., Graff‐Radford, J., Algeciras‐Schimnich, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14629 · Cited by 8
Zhang, Y., Yang, Y., Hu, Z., Zhu, M., Qin, S., Yu, P., Li, B., Xu, J., Ondrejčák, T., Klyubin, I. V., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220351 · Cited by 8
Cheng, Y., Lin, Y., Lin, Y., Hong, W., Kuan, Y., Wu, K.-Y., Hsu, J., Wang, P., Pai, M., Chen, C., et al. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.01.018 · Cited by 8
Targeting Calpain-2 for Alzheimer’s Disease Treatment
Arnsten, A. F. T., & Baudry, M. (2023) · Medical Research Archives · doi:10.18103/mra.v11i2.3487 · Cited by 7
Bibliometric analysis of global research on the role of apolipoprotein E in Alzheimer's disease
Wang, Z., Zhu, X., Wen, Y., & Shang, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17987 · Cited by 7
An EWAS of dementia biomarkers and their associations with age, African ancestry, and PTSD
Miller, M. W., Wolf, E. J., Zhao, X., Logue, M. W., & Hawn, S. E. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01649-3 · Cited by 7
Kinase inhibition in Alzheimer’s disease
Bagheri, S., & Saboury, A. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00003-x · Cited by 7
Hassouneh, A., Bazuin, B. J., Danna‐dos‐Santos, A., Acar, I., Abdel-Qader, I. M., & Initiative, T. A. D. N. (2024) · Digital Biomarkers · doi:10.1159/000538486 · Cited by 7
“However, it can be used to assess the amount of accumulation over time or compare the levels of these proteins in various people ’ s brains, as well as to identify people with various stages of AD and other neurodegenerative diseases [41].”
BackgroundGauthier, S. G., Therriault, J., Pascoal, T. A., & Rosa‐Neto, P. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1841637 · Cited by 7
Cente, M., Peráčková, J., Peráček, P., Majdán, M., Tóth, I., Mikulič, M., Hanes, J., Špajdel, M., Sivčo, P., Skrabanova, M., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01127-8 · Cited by 6
Imaging and plasma biomarkers for pathological accumulation in Down syndrome
Wisch, J. K., Jiao, Z., Kennedy, J. T., Cohen, A. D., Schlachetzki, Z., Petersen, M. E., Handen, B. L., Christian, B. T., Mapstone, M., Rosas, H. D., et al. (2025) · Brain · doi:10.1093/brain/awaf418 · Cited by 7
Chen, Z., Chang, F., Yao, L., Yuan, F., Hong, J., Wu, D., & Wei, Y. (2021) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-021-07143-3 · Cited by 6
Böken, D., Cox, D., Burke, M., Lam, J. Y. L., Katsinelos, T., Danial, J. S. H., Fertan, E., McEwan, W. A., Rowe, J. B., & Klenerman, D. (2024) · Angewandte Chemie · doi:10.1002/ange.202317756 · Cited by 6
Lee, D., Park, J., Jung, K. S., Kim, J., Jang, J. S., Kwon, S., Byun, M. S., Yi, D., Byeon, G., Jung, G., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00719-3 · Cited by 6
Shim, Y. (2023) · Current Alzheimer Research · doi:10.2174/0115672050284054240119101834 · Cited by 6
Detection of Glymphatic Outflow of Tau from Brain to Cerebrospinal Fluid in Mice
Ishida, K., & Yamada, K. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3629-9_19 · Cited by 6
Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging.
Farvadi, F., Hashemi, F., Amini, A., Vakilinezhad, M. A., & Raee, M. J. (2023) · PubMed Central · doi:10.22088/ijmcm.bums.12.2.172 · Cited by 6
Metadata
- Authors
- Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Barthélemy, Nicolas R.
- Bateman, Randall J.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-07-28
- Volume
- 217
- Issue
- 11
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7596823
- OpenAlex
- W3045987239
- Cited by
- 437
- References
- 36
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 72 · 2023: 64 · 2022: 82 · 2021: 71 · 2020: 19
- FWCI
- 35.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- Alzheimer’s Association (AARF-16-443265)
- Rainwater Charitable Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS095773)
- Tau SILK Consortium
- AbbVie
- Biogen
- Eli Lilly and Company
- Coins for Alzheimer’s Research Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau isoforms, CSF tau, plasma biomarkers, amyloid plaques, beta-amyloidosis, diagnostic accuracy, tau truncation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Phosphorylation, Mass Spectrometry, Cohort Studies, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.